Semaglutide 2.4mg weekly (STEP-1 trial) produced 14.9% mean body weight reduction at 68 weeks
Persistent neurological symptoms, abnormal blood test results, or changes in health status warrant medical review and potential dose adjustment
K50.0 Crohns Disease of Small Intestine K50.1 Crohns Disease of Large Intestine K50.8 Crohns Disease of Both Small and Large Intestine (Ileocolitis) K50.9 Crohns Disease, Unspecified Associated and Complication Codes For enteropathic arthropathy (M07.6x) , ICD-10-CM guidelines require sequencing the underlying IBD (K50.x) as the principal/first-listed diagnosis
This IV is great for people with inflammatory conditions such as RA, psoriasis/ eczema, IBD, migraines, and/or headaches
Measure carefully with a 3 mL syringe, not an insulin syringe which maxes out at 1 mL and would require multiple draws